Abstract:Background Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to assess non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis. Methods We did a randomised, prospective, double-blind, double-dummy, controlled trial comparing posaconazole (intravenous or oral posaconazole 300 mg twice on day 1, followed by 300 mg once a day for days 2-84) with voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2-84) for 12 weeks or less in the primary treatment of invasive aspergillosis. Participants were from 91 study sites in 26 countries, were aged 13 years or older, weighed at least 40 kg, and met criteria for proven, probable, or possible fungal disease. Participants were randomly assigned (1:1) via a computer-generated randomisation schedule with stratification by risk status. The primary endpoint was cumulative all-cause mortality up until day 42 in the intention-to-treat (ITT) population (defined as randomly assigned participants who received >= 1 dose of study drug), with a 10% non-inferiority margin. The ITT population was also evaluated for safety. This study is registered with ClinicalTrials.gov, NCT01782131, and EudraCT, 2011-003938-14. Findings Between Oct 25, 2013, and Sept 10, 2019, of 653 individuals assessed for eligibility, 575 ITT participants were randomly assigned and received one or more doses of study drug (n=288 [50%] posaconazole, n=287 [50%] voriconazole). Mortality up until day 42 was 15% (44 of 288) in the posaconazole group and 21% (59 of 287) in the voriconazole group (treatment difference -5.3% [95% CI -11.6 to 1.0]; p<0.0001). Mortality up until day 42 in the full- analysis-set subpopulation (ITT participants with proven or probable invasive aspergillosis) supported this conclusion: 31 (19%) of 163 participants in the posaconazole group and 32 (19%) of 171 participants in the voriconazole group (treatment difference 0.3% [95% CI -8.2 to 8.8]). The most frequently reported treatmentrelated adverse events (incidence >3%) were increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT), nausea, hypokalaemia, and vomiting in the posaconazole group and increased ALT, AST, or alkaline phosphatase, hallucination, increased gamma-glutamyltransferase peptidase, nausea, and blurred vision in the voriconazole group. The overall incidence of treatment-related adverse event rates in the ITT population was 30% for posaconazole and 40% for voriconazole (treatment difference - 10. 2% [95% CI -17 .9 to - 2.4]). Interpretation Posaconazole was non-inferior to voriconazole for all-cause mortality up until day 42 in participants with invasive aspergillosis. Posaconazole was well tolerated, and participants had fewer treatment-related adverse events than in the voriconazole group. This study supports the use of posaconazole as a first-line treatment for the condition.

Voriconazole as an alternative oral treatment in fluconazole-resistant urinary candidiasis

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

Increasing rate of non- Candida albicans yeasts and fluconazole resistance in yeast isolates from women with recurrent vulvovaginal candidiasis in Leeds, United Kingdom

A Pilot Study Showing Fluconazole and Flucytosine Activities against Candida glabrata are Affected by Low pH: Implications for the Treatment of Recurrent Vulvovaginal Candidiasis

Voriconazole plasma concentration monitoring in patients

A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates

Posaconazole Vs. Fluconazole As Invasive Fungal Infection Prophylaxis in China: A Multicenter, Randomized, Open-Label Study

A Randomized Clinical Trial of the Efficacy and Safety of Terconazole Vaginal Suppository Versus Oral Fluconazole for Treating Severe Vulvovaginal Candidiasis.

Pharmacokinetics and safety of two Voriconazole formulations after intravenous infusion in two doses in healthy Chinese subjects

In Vitro Fluconazole and Nystatin Susceptibility and Clinical Outcome in Complicated Vulvovaginal Candidosis.

Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis.

Safety, Tolerability, and Pharmacokinetics of Voriconazole for Injection in Two Preparations in Chinese Healthy Adult Volunteers

Terbinafine Versus Itraconazole and Fluconazole in the Treatment of Vulvovaginal Candidiasis

Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management

Efficacy And Safety Comparison Between Intravenous And Oral Voriconazole: A Systematic Review And Meta-Analysis

Oteseconazole Versus Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis: a Multicenter, Randomized, Double-Blinded, Phase 3 Trial.

Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo

Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients

Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions

The Efficacy and Safety of Clotrimazole Vaginal Tablet Vs. Oral Fluconazole in Treating Severe Vulvovaginal Candidiasis.

Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing